What will It take to have the Government accept that stealth adapted viruses are infecting humans? Hopefully, this article may do so. Health Officials first learned about stealth adapted viruses in 1995. They balked, however, upon hearing that some of these viruses originated in the type of monkey used to produce polio vaccines.
The Food and Drug Administration (FDA) recognized the probable contamination of some polio vaccines in monkey studies performed in 1972. Yet, public health officials chose to not publicly disclose these studies. It would have raised questions regarding the basic decision to use monkey kidney cells to produce live polio vaccine. Acknowledging this error would also expose the potential origin of HIV, the AIDS virus, from the experimental testing of contaminated polio vaccines in Africa.
AIDS is not the only price that mankind has paid in return for developing polio vaccines. The contaminating vaccine-derived viruses are now being transmitted between humans. The viruses are a major cause of many illnesses, which predominantly affect the brain. The illnesses include autism, mental diseases, chronic fatigue syndrome, fibromyalgia, addiction and criminal behaviors.It is no longer acceptable for public health officials to avoid the issue of stealth adapted viruses. They need to respond to those with virus damaged brains; those who care for them; and those who are harmed by brain-damaged criminals.
The decision to use monkeys for polio vaccines started in 1948 when Dr. John Enders showed that polio virus could be grown in monkey cell cultures. Dr. Enders then stood back as Drs. Jonas Salk, Albert Sabin and Hilary Koprowski raced towards developing a polio vaccine. They chose to use normal cells, which were available from monkeys, rather than an established human cell line to grow the polio virus. This decision addressed the public's concern that the use of cell lines could possibly lead to cancer in the vaccine recipients. This unfounded risk overshadowed the known risks of using monkeys, which were known carriers of different viruses.Dr. Salk was the early victor with his development of an inactivated vaccine. Dr. Sabin knew better than Dr. Koprowski how to select non-contaminated, attenuated (weakened) live polio virus isolates. Dr. Koprowski tested his less-purified "CHAT" live polio vaccine in African chimpanzees. He did so even after being told by Dr. Sabin that the CHAT vaccine was contaminated with another virus. Moreover, the CHAT vaccine was clearly inducing illness in chimpanzees and in some of the animal handlers (referred to as the thin man syndrome). The CHAT vaccine has since been shown to contain DNA of rhesus monkey cytomegalovirus. This is important since cytomegaloviruses can promote the growth of retroviruses. It is likely that the contaminated CHAT vaccine led to HIV developing from the chimpanzee simian immunodeficiency virus (SIV). Various publications suggesting that HIV arose in the 1920's are flawed.BIn the early 1960's it was realized that many rhesus monkeys are infected with simian virus-40 (SV40). This led to the decision to switch the production of polio vaccines to kidney cells of African green monkeys. Another important switch was to replace Dr. Salk's inactivated polio vaccine with the live attenuated polio vaccine developed by Dr. Sabin.In 1991, I cultured an atypical cytomegalovirus from a patient with the chronic fatigue syndrome (CFS). A similar virus was cultured from a patient with a bipolar psychotic illness. In 1995, I published and personally notified the FDA and the polio vaccine manufacturer that the cultured cytomegaloviruses had originated in African green monkeys. They were, therefore, likely past contaminants of prior polio vaccines, which were now being passed between humans and even between humans to animals. This unequivocal finding, along with the likely relevance to the AIDS epidemic, were shunned by the FDA, Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH). Indeed, these organizations made efforts to hinder further research on the topic.
A novel aspect of the viruses is the capacity to induce cellular damage when inoculated into animals, yet not evoke an inflammatory response. This meant that cell-damaging viruses could evade cellular immunity, a process that is called "stealth adaption." I subsequently cultured cytopathic (cell damaging) viruses from numerous patients with a range of illnesses, most noticeably involving the brain. The patients included those with major psychiatric and neurological illnesses and included many adults with the chronic fatigue syndrome and many children with autism and behavioral/learning disorders.
Only some of the cultured atypical viruses were of monkey origin. Indeed, stealth adaptation is a generic process that can potentially occur with all viruses. It arises from the loss or mutation of the relatively few virus-coded components which comprise the major antigens targeted by the cellular immune system. By avoiding the connection with African green monkeys, public health officials have essentially disregarded the entire concept of stealth adaptation.
A more widespread understanding of stealth adapted viruses will shed light on to the infectious origin of many neuropsychiatric illnesses that can be transmitted between family members and be occupationally acquired. Knowing about stealth adapted viruses will also help shift the focus of psychiatry away from therapies based on altering the levels of neurotransmitters.
Indeed, ongoing research has identified an important pathway by which the body can not only suppress infections due to stealth adapted viruses but can also effectively suppress regular viruses and other infectious agents. The non-immunological defense mechanism is referred to as the alternative cellular energy (ACE) pathway. It is expressed as a dynamic (kinetic) activity of the body's fluids that supports several cellular functions beyond those dependent on cellular energy obtained from the metabolism of food.
It is further proposed that the ACE pathway involves the absorption of an external energy, referred to as KELEA (kinetic energy limiting electrostatic attraction). An intriguing additional hypothesis is that certain forms of fluctuating electrical activities of the brain and possibly of muscles can function as a natural antenna to bring KELEA into the body. KELEA activated water and various water activating compounds can be administered to patients as a means of enhancing the body's ACE pathway. Since therapies are available, there should be no further delays in public health officials acknowledging the prior research on stealth adapted viruses. Much of the research on stealth adapted viruses, alternative cellular energy (ACE) and KELEA activated water is readily available in online publications. Indeed, a book with the above title was published in 2014.
Therapeutic trials on methods to enhance the ACE pathway in patients with various clinical illnesses need to be prioritized by clinicians treating patients with brain-damaging illnesses. Useful clinical experience can also be gained using waterceutical™ to treat patients with numerous illnesses attributed insufficient cellular energy (ICE)™ from the metabolism of food. HIV, hepatitis viruses, herpes viruses can be suppressed via the ACE pathway, as can drug-resistant tuberculosis, tropical diarrhea, and other bacterial infections. Many cancers can be explained as ICE preventing tumor cell death by apoptosis. Providing additional energy via the ACE pathway can reasonably be expected to lead to tumor regression. The ACE pathway has anti-inflammatory properties and waterceuticals™ should be first-line therapy for acute burns and possibly internal injuries due to ischemia, such as strokes and heart attacks. The Government should assist in organizing and coordinating such clinical endeavors.
A three-prong approach is envisioned to create this new paradigm in medicine. The most critical is well conducted clinical trials to establish and to optimize efficacy. A supporting effort is needed to provide waterceuticals™ using various water activating methods, which can be compared among each other for the various clinical applications. This facet will require large-scale production and distribution facilities, with potential input from the many agricultural and industrial uses of activated fluids.
The Food and Drug Administration (FDA) recognized the probable contamination of some polio vaccines in monkey studies performed in 1972. Yet, public health officials chose to not publicly disclose these studies. It would have raised questions regarding the basic decision to use monkey kidney cells to produce live polio vaccine. Acknowledging this error would also expose the potential origin of HIV, the AIDS virus, from the experimental testing of contaminated polio vaccines in Africa.
AIDS is not the only price that mankind has paid in return for developing polio vaccines. The contaminating vaccine-derived viruses are now being transmitted between humans. The viruses are a major cause of many illnesses, which predominantly affect the brain. The illnesses include autism, mental diseases, chronic fatigue syndrome, fibromyalgia, addiction and criminal behaviors.It is no longer acceptable for public health officials to avoid the issue of stealth adapted viruses. They need to respond to those with virus damaged brains; those who care for them; and those who are harmed by brain-damaged criminals.
The decision to use monkeys for polio vaccines started in 1948 when Dr. John Enders showed that polio virus could be grown in monkey cell cultures. Dr. Enders then stood back as Drs. Jonas Salk, Albert Sabin and Hilary Koprowski raced towards developing a polio vaccine. They chose to use normal cells, which were available from monkeys, rather than an established human cell line to grow the polio virus. This decision addressed the public's concern that the use of cell lines could possibly lead to cancer in the vaccine recipients. This unfounded risk overshadowed the known risks of using monkeys, which were known carriers of different viruses.Dr. Salk was the early victor with his development of an inactivated vaccine. Dr. Sabin knew better than Dr. Koprowski how to select non-contaminated, attenuated (weakened) live polio virus isolates. Dr. Koprowski tested his less-purified "CHAT" live polio vaccine in African chimpanzees. He did so even after being told by Dr. Sabin that the CHAT vaccine was contaminated with another virus. Moreover, the CHAT vaccine was clearly inducing illness in chimpanzees and in some of the animal handlers (referred to as the thin man syndrome). The CHAT vaccine has since been shown to contain DNA of rhesus monkey cytomegalovirus. This is important since cytomegaloviruses can promote the growth of retroviruses. It is likely that the contaminated CHAT vaccine led to HIV developing from the chimpanzee simian immunodeficiency virus (SIV). Various publications suggesting that HIV arose in the 1920's are flawed.BIn the early 1960's it was realized that many rhesus monkeys are infected with simian virus-40 (SV40). This led to the decision to switch the production of polio vaccines to kidney cells of African green monkeys. Another important switch was to replace Dr. Salk's inactivated polio vaccine with the live attenuated polio vaccine developed by Dr. Sabin.In 1991, I cultured an atypical cytomegalovirus from a patient with the chronic fatigue syndrome (CFS). A similar virus was cultured from a patient with a bipolar psychotic illness. In 1995, I published and personally notified the FDA and the polio vaccine manufacturer that the cultured cytomegaloviruses had originated in African green monkeys. They were, therefore, likely past contaminants of prior polio vaccines, which were now being passed between humans and even between humans to animals. This unequivocal finding, along with the likely relevance to the AIDS epidemic, were shunned by the FDA, Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH). Indeed, these organizations made efforts to hinder further research on the topic.
A novel aspect of the viruses is the capacity to induce cellular damage when inoculated into animals, yet not evoke an inflammatory response. This meant that cell-damaging viruses could evade cellular immunity, a process that is called "stealth adaption." I subsequently cultured cytopathic (cell damaging) viruses from numerous patients with a range of illnesses, most noticeably involving the brain. The patients included those with major psychiatric and neurological illnesses and included many adults with the chronic fatigue syndrome and many children with autism and behavioral/learning disorders.
Only some of the cultured atypical viruses were of monkey origin. Indeed, stealth adaptation is a generic process that can potentially occur with all viruses. It arises from the loss or mutation of the relatively few virus-coded components which comprise the major antigens targeted by the cellular immune system. By avoiding the connection with African green monkeys, public health officials have essentially disregarded the entire concept of stealth adaptation.
A more widespread understanding of stealth adapted viruses will shed light on to the infectious origin of many neuropsychiatric illnesses that can be transmitted between family members and be occupationally acquired. Knowing about stealth adapted viruses will also help shift the focus of psychiatry away from therapies based on altering the levels of neurotransmitters.
Indeed, ongoing research has identified an important pathway by which the body can not only suppress infections due to stealth adapted viruses but can also effectively suppress regular viruses and other infectious agents. The non-immunological defense mechanism is referred to as the alternative cellular energy (ACE) pathway. It is expressed as a dynamic (kinetic) activity of the body's fluids that supports several cellular functions beyond those dependent on cellular energy obtained from the metabolism of food.
It is further proposed that the ACE pathway involves the absorption of an external energy, referred to as KELEA (kinetic energy limiting electrostatic attraction). An intriguing additional hypothesis is that certain forms of fluctuating electrical activities of the brain and possibly of muscles can function as a natural antenna to bring KELEA into the body. KELEA activated water and various water activating compounds can be administered to patients as a means of enhancing the body's ACE pathway. Since therapies are available, there should be no further delays in public health officials acknowledging the prior research on stealth adapted viruses. Much of the research on stealth adapted viruses, alternative cellular energy (ACE) and KELEA activated water is readily available in online publications. Indeed, a book with the above title was published in 2014.
Therapeutic trials on methods to enhance the ACE pathway in patients with various clinical illnesses need to be prioritized by clinicians treating patients with brain-damaging illnesses. Useful clinical experience can also be gained using waterceutical™ to treat patients with numerous illnesses attributed insufficient cellular energy (ICE)™ from the metabolism of food. HIV, hepatitis viruses, herpes viruses can be suppressed via the ACE pathway, as can drug-resistant tuberculosis, tropical diarrhea, and other bacterial infections. Many cancers can be explained as ICE preventing tumor cell death by apoptosis. Providing additional energy via the ACE pathway can reasonably be expected to lead to tumor regression. The ACE pathway has anti-inflammatory properties and waterceuticals™ should be first-line therapy for acute burns and possibly internal injuries due to ischemia, such as strokes and heart attacks. The Government should assist in organizing and coordinating such clinical endeavors.
A three-prong approach is envisioned to create this new paradigm in medicine. The most critical is well conducted clinical trials to establish and to optimize efficacy. A supporting effort is needed to provide waterceuticals™ using various water activating methods, which can be compared among each other for the various clinical applications. This facet will require large-scale production and distribution facilities, with potential input from the many agricultural and industrial uses of activated fluids.